In 2025, manufacturers and distributors shipped 4,421 grams of amphetamine per 100,000 people to pharmacies and other DEA-registered buyers in New Mexico: less than half the U.S. figure of 9,135 grams, and the third-lowest of the 50 states and the District of Columbia, according to the DEA’s ARCOS shipment records.
Key numbers
The seven states compared
New Mexico received the least of the three medicines per person of any of the seven states we serve. Colorado received the most amphetamine and lisdexamfetamine, and Washington the most methylphenidate.
| State | Amphetamine | Lisdexamfetamine | Methylphenidate |
|---|---|---|---|
| Texas | 8,314 (42nd) | 4,442 (32nd) | 4,904 (44th) |
| New Mexico | 4,421 (49th) | 1,330 (50th) | 3,597 (48th) |
| Florida | 8,469 (37th) | 3,181 (45th) | 4,441 (46th) |
| Alaska | 7,028 (45th) | 4,435 (33rd) | 5,953 (39th) |
| Arizona | 8,355 (41st) | 3,830 (42nd) | 5,354 (42nd) |
| Colorado | 10,596 (22nd) | 4,518 (31st) | 6,450 (35th) |
| Washington | 9,346 (31st) | 4,193 (39th) | 7,464 (25th) |
| U.S. total | 9,135 | 4,332 | 6,191 |
How supply changed, 2021 to 2025
Shipments per person rose in all seven states for all three medicines. Nationally, amphetamine rose 21%, lisdexamfetamine 50% and methylphenidate 20%. New Mexico’s amphetamine figure rose 31%, but it was the lowest of the seven states in every year from 2021 to 2025.
| State | Amphetamine 2021 | Amphetamine 2025 | Change | Lisdexamfetamine change | Methylphenidate change |
|---|---|---|---|---|---|
| Texas | 7,370 | 8,314 | +13% | +37% | +14% |
| New Mexico | 3,380 | 4,421 | +31% | +93% | +14% |
| Florida | 7,471 | 8,469 | +13% | +27% | +18% |
| Alaska | 5,096 | 7,028 | +38% | +126% | +36% |
| Arizona | 6,442 | 8,355 | +30% | +51% | +25% |
| Colorado | 7,995 | 10,596 | +33% | +92% | +36% |
| Washington | 7,199 | 9,346 | +30% | +99% | +26% |
| U.S. total | 7,544 | 9,135 | +21% | +50% | +20% |
What this means for patients and families
- Supply differs widely between the states we serve. In 2025, Colorado received 2.4 times as much amphetamine per person as New Mexico, and New Mexico had the least of the seven states for all three medicines.
- A state total is not a pharmacy shelf. ARCOS adds up a year of shipments to a whole state. It cannot show whether one pharmacy has a particular medicine and strength in stock on the day you need it, so calling your pharmacy a few days before a refill is due is still the surest check.
- Shortages are tracked separately. As of November 11, 2026, the FDA drug shortage database lists mixed amphetamine salts tablets, lisdexamfetamine capsules, lisdexamfetamine chewable tablets, extended-release methylphenidate film and extended-release methylphenidate tablets as current shortages.
- Prescribing rules differ by state too. Texas does not let nurse practitioners prescribe Schedule II medications, which include the main stimulants, outside hospital and hospice settings, so stimulant prescriptions for Willow & Stone’s Texas patients are written by the collaborating physician who works with Dr. Forbes. In the other six states, ask the practice before you book how stimulant prescriptions are handled. Our guide to ADHD medication and telehealth rules covers each state.
Method
Manufacturers and distributors report their sales of Schedule II drugs, including these three medicines, to the DEA’s Automated Reports and Consolidated Ordering System (ARCOS). Each year the DEA publishes a Retail Drug Summary of those sales to pharmacies, hospitals, practitioners and other DEA-registered buyers.
We used Report 04, which gives each state’s total grams for the calendar year and its grams per 100,000 people, for three DEA drug codes: amphetamine (1100; the DEA lists Adderall and Dexedrine among its other names), lisdexamfetamine (1205; Vyvanse) and methylphenidate (1724, all isomers; Concerta, Ritalin and Methylin), from the DEA’s list of controlled substances. We took the five reports for calendar 2021 to 2025; the 2025 report was run on June 30, 2026.
Our script reads the tables from the DEA’s PDF files and checks them: each printed rate equals grams divided by population, the states add up to the DEA’s U.S. total, and the DEA’s population for each state is the 2020 Census count. We ranked the 50 states and the District of Columbia ourselves. Report 07 shows who bought the medicine: in 2025, pharmacies received 97.4% of the amphetamine, 98.1% of the lisdexamfetamine and 97.2% of the methylphenidate shipped nationally.
Limits of the data
- Shipments, not people. ARCOS counts grams shipped to buyers in a state. It does not count patients, prescriptions or doses, and it does not record what a medicine was prescribed for. It cannot say whether a lower figure reflects less demand, fewer prescribers, different prescribing habits or harder-to-find stock.
- One medicine at a time. Each medicine is reported separately. We compare states within each medicine and never add grams of different medicines together.
- Counted where the buyer is. ARCOS places each sale at the buyer’s registered location (Report 01 groups sales by the buyer’s ZIP code), so medicine that a pharmacy mails to a patient in another state counts in the pharmacy’s state.
- A fixed population. The DEA divides by the 2020 Census count in every year. For a state that has grown since then, later per-person figures run slightly high.
- The U.S. total includes territories. The DEA’s national figure also covers Puerto Rico, Guam, the U.S. Virgin Islands and American Samoa. Our ranks cover the 50 states and the District of Columbia only, so they can differ from the DEA’s printed ranks.
- Revisions. The DEA notes that ARCOS reports can be updated and corrected without notice. Our figures are from the reports as downloaded on November 11, 2026.
Sources
- DEA Diversion Control Division, ARCOS Retail Drug Summary, calendar 2021 (run April 7, 2022), Report 04: www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2021.pdf
- DEA Diversion Control Division, ARCOS Retail Drug Summary, calendar 2022 (run August 1, 2023), Report 04: www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2022.pdf
- DEA Diversion Control Division, ARCOS Retail Drug Summary, calendar 2023 (run May 31, 2024), Report 04: www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2023.pdf
- DEA Diversion Control Division, ARCOS Retail Drug Summary, calendar 2024 (run June 26, 2025), Report 04: www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2024.pdf
- DEA Diversion Control Division, ARCOS Retail Drug Summary, calendar 2025 (run June 30, 2026), Reports 04 and 07: www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2025.pdf
- DEA Diversion Control Division, ARCOS overview: www.deadiversion.usdoj.gov/arcos/arcos.html
- DEA, Controlled Substances in Alphabetical Order (drug codes and other names): www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
- FDA Drug Shortages database, as of November 11, 2026, read through the openFDA drug shortages API: dps.fda.gov/drugshortages
- U.S. Census Bureau, 2020 Census apportionment results, resident population by state: census.gov apportionment table (XLSX)
- Texas Occupations Code § 157.0511 (delegation of Schedule II prescribing): texas.public.law/statutes/tex._occ._code_section_157.0511
Cite this study
Willow & Stone Integrative Mental Health. “ADHD Medication Supply in the Seven States We Serve, 2025.” Published November 11, 2026. https://willowandstonehealth.com/research/adhd-medication-supply-by-state/. Data: DEA ARCOS Retail Drug Summary, 2021 to 2025.
Download the data (CSV): all 50 states, the District of Columbia and the U.S. total, three medicines, 2021 to 2025, in grams and grams per 100,000 people. Free to reuse under CC BY 4.0 with credit to Willow & Stone Integrative Mental Health and a link to this page.
Spotted an error? Contact us and we will correct it and note the change on this page.
This page reports public supply data. It is not medical advice and does not say whether any medicine is right for anyone; that decision belongs to you and a clinician who has evaluated you.
If you need help right now
Willow & Stone is an outpatient practice and is not an emergency service. If you or someone you care about is in immediate danger, call 911. For urgent mental health support at any hour, call or text 988 to reach the Suicide & Crisis Lifeline, or text HOME to 741741 for the Crisis Text Line. Both are free, confidential, and available 24/7 nationwide.
About this research
Willow & Stone Integrative Mental Health is a telehealth psychiatric practice for people in Texas, New Mexico, Florida, Alaska, Arizona, Colorado and Washington. This study uses public federal data only and contains no patient information.